



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 12:27
Last Report Issued 02/01/2013 09:33

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2397SP-POS
Patient ID 2397SP-POS
Chain 13000583
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 13000583
Received 01/30/2013 11:56

Sample ID 13000583-001
Matrix Serum or Plasma
Patient Name 2397SP-POS
Patient ID 2397SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

2397SP Indapamide, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Indapamide	500	ng/mL	10	ELEVATED
Synonym(s): Lozol®				

Normal subjects taking 2.5 mg daily normal release indapamide had steady state peak blood concentrations of 150 +/- 35 ng/mL. The blood to plasma ratio for indapamide is approximately 6.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.